Nihon rinsho. Japanese journal of clinical medicine · 2017
[Tax-targeted DC vaccine for ATL].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suehiro Youko
Аннотация
ATL is a HTLV-1 induced T-cell malignancy with extremely poor prognosis. HTLV-1 Tax which is regulatory protein encoded in the pX region plays a crucial role in HTLV-1 leukemo- genesis and is a major target antigen for CTL. We conducted a clinical trial of Tax targeted therapeutic vaccine consisting of autologous dendritic cells (Tax-DC). The good quality of lives and long-term treatment-free survival were observed for more than 3 years in two of three patients enrolled in the pilot study. Tax-specific proliferative CTL responses were ob- served in all cases and the sporadic augmented responses also have been detected subse- quently. Tax-DC vaccine might be a well-tolerated and long-lasting maintenance therapy that is acceptable for even elderly patients.